Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of ...

A new drug tested in a phase 3 trial showed significant improvement in patients with treatment-resistant ovarian cancer. Researchers discuss the findings.

Results showed the ORR was 17.1% in the tovecimig plus paclitaxel arm compared with 5.3% in the paclitaxel alone arm. Topline data were announced from a phase 2/3 trial evaluating tovecimig in ...

Investigators conducted a 4T1 breast cancer mouse model study to assess whether a combination of Shenhuang plaster, an herbal formula, plus paclitaxel could enhance the anti-tumor effects of ...

Cipla said USFDA has approved the ANDA submitted for Paclitaxel Protein-bound Particles for Injectable Suspension (albumin-bound), 100 mg/vial, Single-Dose Vial ('Protein-bound Paclitaxel') on Apr 10 ...

AstraZeneca Plc (NASDAQ:AZN) on Monday released topline data from the DESTINY-Breast09 Phase 3 trial of Enhertu (5.4mg/kg) ...

Enfortumab vedotin is now available for patients who received prior platinum-containing chemotherapy and a PD-1/L1 inhibitor ...

The firm stated that it is now set to introduce the product in the United States in H1FY26, earlier than anticipated.

Drug major Cipla on Friday said it has received approval from the US health regulator to market a generic cancer treatment ...

Drs Ursula A. Matulonis and Gini F. Fleming discuss the state of endometrial cancer, the role of immunotherapy, and ...